WINTON GROUP Ltd Invests $14.22 Million in Thermo Fisher Scientific Inc. $TMO

WINTON GROUP Ltd bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, HoldingsChannel reports. The fund bought 28,360 shares of the medical research company’s stock, valued at approximately $14,219,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TMO. Bank OZK acquired a new stake in Thermo Fisher Scientific in the second quarter valued at $1,096,000. Ausdal Financial Partners Inc. acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth $456,000. North Dakota State Investment Board bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $7,505,000. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $15,501,867,000. Finally, German American Bancorp Inc. bought a new position in shares of Thermo Fisher Scientific during the second quarter worth about $4,920,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 28th. UBS Group upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $540.00 to $730.00 in a research report on Tuesday. BMO Capital Markets lowered Thermo Fisher Scientific to a “market perform” rating in a research report on Wednesday. Citigroup cut Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $624.64.

Thermo Fisher Scientific Trading Up 0.7%

Shares of NYSE:TMO opened at $607.23 on Thursday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $647.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a market cap of $224.52 billion, a PE ratio of 32.66, a P/E/G ratio of 2.52 and a beta of 0.85. The company’s 50-day moving average price is $577.00 and its 200 day moving average price is $517.24.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.